Medtronic, one of the world’s largest medical device makers, announced on September 1, 2026 that it is investing roughly $700 million in a strategic partnership with Cornerstone Robotics, a move that gives the company distribution rights to a competing surgical robot even as it continues rolling out its own AI-assisted platform. The deal is a striking example of a market leader effectively hedging its bets in one of medtech’s fastest-growing segments: robotic-assisted surgery, where AI-driven precision tools are increasingly seen as standard rather than optional equipment in operating rooms.
The mechanics of the deal
Under the agreement, Medtronic gains rights to distribute Cornerstone Robotics’ Sentire surgical system in select markets outside the United States where the device already has regulatory approval. Cornerstone Robotics is led by founder and chief executive Samuel Au, whose company has been building out Sentire as an alternative robotic-assisted surgery platform. Rather than treating Sentire purely as a competitive threat to Medtronic’s own Hugo robotic-assisted surgery system, the company is folding it into its commercial portfolio. Matt Anderson, Medtronic’s senior vice president and president of its surgical business, said the company is “investing across robotic platforms” because surgeons, health systems and different national markets have varying needs and preferences that a single robotic system cannot always meet.
Where each robot stands today
The two platforms are at different stages of global rollout. Medtronic’s Hugo system has received FDA clearance within the past year and is already in use across more than 35 countries on six continents, with the company projecting that procedures performed on Hugo will exceed 50,000 globally by the end of its current fiscal year. Cornerstone’s Sentire system, by comparison, is earlier in its regulatory journey: it received a CE Mark in May 2026, clearing it for use in the European Union, and has also secured approval in China and Singapore, but it has not yet been cleared for use in the United States. The Medtronic partnership effectively gives Sentire a much larger distribution engine to reach international markets faster than Cornerstone could likely manage on its own.
Why Medtronic wants two robots instead of one
The rationale behind backing a rival platform rather than competing head-on becomes clearer in the context of the overall market: robotic-assisted surgery adoption remains in the single digits globally as a share of eligible procedures, according to figures cited around the deal, meaning the near-term opportunity is less about stealing share from competitors and more about converting traditional open and laparoscopic surgery to any robotic-assisted approach. Cornerstone’s Au said in comments about the partnership that “physicians and patients alike will be the greatest beneficiaries,” a framing that emphasizes expanding overall access rather than a zero-sum contest between the two robots. For Medtronic, offering multiple platforms could also help it serve hospital systems and surgeons with different budgets, procedure volumes or clinical preferences without ceding those accounts entirely to a competitor.
The broader market backdrop
The deal lands amid rapid growth projections for the surgical robotics sector. Industry market research puts the global surgical robots market at roughly $10.6 billion in 2026, with forecasts calling for growth to nearly $23 billion by 2035, an annual growth rate of close to 9%, driven by rising demand for minimally invasive procedures, greater surgical precision, and improving patient outcomes across specialties including general surgery, orthopedics, urology, and abdominal and pelvic surgery. AI integration is a central part of that growth story: modern robotic platforms increasingly incorporate machine-learning-driven navigation, tissue recognition and motion-scaling features that go well beyond the earlier generation of robots, which were largely mechanical extensions of a surgeon’s hands with limited computational assistance.
Reasons for caution
Not every industry observer views the rapid expansion of robotic-assisted surgery as an unambiguous win. Some health-policy researchers have pointed out that robotic systems carry substantial upfront capital costs and ongoing per-procedure licensing fees that get passed on through hospital billing, without robust long-term data proving that robotic approaches consistently produce better outcomes than skilled surgeons using conventional laparoscopic techniques for many procedure types. There are also open questions about training: as more platforms enter the market, hospitals and surgeons face a growing burden of learning multiple robotic systems, each with different interfaces and AI-assisted features, which could offset some of the efficiency gains robotics is meant to deliver. Regulatory scrutiny is also likely to increase as AI-driven surgical systems become more autonomous in tasks like tissue identification and suturing guidance, an area where oversight bodies have signaled they want more robust safety validation before granting broader autonomy.
What comes next
Watch for Cornerstone Robotics to pursue FDA clearance for Sentire in the U.S. market, a step that would let Medtronic’s distribution reach extend into its largest single market. Medtronic, meanwhile, is on track to cross the 50,000-procedure milestone for Hugo by its fiscal year-end, a figure likely to be closely tracked by investors and competitors like Intuitive Surgical as a proxy for how quickly robotic-assisted surgery is displacing traditional approaches. The bigger test will be whether running two robotic platforms in parallel actually accelerates adoption in underserved markets, or whether it simply adds complexity to Medtronic’s own commercial and support operations.
Photo: 12019 / PIXABAY via Pixabay
